Catalyst Pharmaceutical CPRX Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's deferred tax assets?
- Catalyst Pharmaceutical (CPRX) reported deferred tax assets of $55.11M in Q1 2026.
- How has Catalyst Pharmaceutical's deferred tax assets changed year-over-year?
- Catalyst Pharmaceutical's deferred tax assets increased by 14.3% year-over-year, from $48.22M to $55.11M.
- What is the long-term trend for Catalyst Pharmaceutical's deferred tax assets?
- Over 5 years (2020 to 2025), Catalyst Pharmaceutical's deferred tax assets has grown at a 9.9% compound annual growth rate (CAGR), from $32.97M to $52.77M.
- What does deferred tax assets mean?
- Represents future tax benefits arising from temporary differences between the book value of assets/liabilities and their tax basis, or from carry-forward tax losses. These assets are realized when the firm generates sufficient taxable income to offset these differences. It serves as an indicator of future tax savings potential.